Department of Neurology, The Second Xiangya Hospital, Central South University, Changsha, China.
Department of Neurology, The Second Xiangya Hospital, Central South University, Changsha, China.
Clin Ther. 2019 Oct;41(10):2112-2136. doi: 10.1016/j.clinthera.2019.07.009. Epub 2019 Aug 21.
IV immunoglobulin (Ig) therapy has been widely used for the treatment of neurologic disorders, autoimmune diseases, immunodeficiency-related diseases, blood system diseases, and cancers. In this review, we summarize the efficacy and tolerability of IVIg and SCIg therapy in neurologic diseases.
We summarized and analyzed the efficacy and tolerability of IVIg and SCIg in neurologic diseases, by analyzing the literature pertaining to the use of IVIg and SCIg to treat nervous system diseases.
In clinical neurology practice, IVIg has been shown to be useful for the treatment of new-onset or recurrent immune diseases and for long-term maintenance treatment of chronic diseases. Moreover, IVIg may have applications in the management of intractable autoimmune epilepsy, paraneoplastic syndrome, autoimmune encephalitis, and neuromyelitis optica. SCIg is emerging as an alternative to IVIg treatment. Although SCIg has a composition similar to that of IVIg, the applications of this therapy are different. Notably, the bioavailability of SCIg is lower than that of IVIg, but the homeostasis level is more stable. Current studies have shown that these 2 therapies have pharmacodynamic equivalence.
In this review, we explored the efficacy of IVIg in the treatment of various neurologic disorders. IVIg administration still faces many challenges. Thus, it will be necessary to standardize the use of IVIg in the clinical setting. SCIg administration is a novel and feasible treatment option for neurologic and immune-related diseases, such as chronic inflammatory demyelinating polyradiculoneuropathy and idiopathic inflammatory myopathies. As our understanding of the mechanisms of action of IVIg improve, potential next-generation biologics can being developed.
静脉注射免疫球蛋白（IVIg）治疗已广泛用于治疗神经疾病、自身免疫性疾病、免疫缺陷相关疾病、血液系统疾病和癌症。在这篇综述中，我们总结了 IVIg 和 SCIG 在神经疾病中的疗效和耐受性。
我们通过分析关于 IVIg 和 SCIG 治疗神经系统疾病的文献，总结和分析了 IVIg 和 SCIG 在神经疾病中的疗效和耐受性。
在临床神经病学实践中，IVIg 已被证明对治疗新发或复发性免疫性疾病以及慢性疾病的长期维持治疗有用。此外，IVIg 可能在治疗难治性自身免疫性癫痫、副肿瘤综合征、自身免疫性脑炎和视神经脊髓炎方面具有应用价值。SCIG 作为 IVIg 治疗的替代方案正在出现。虽然 SCIG 的组成与 IVIg 相似，但该疗法的应用不同。值得注意的是，SCIG 的生物利用度低于 IVIg，但体内平衡水平更稳定。目前的研究表明，这两种治疗方法具有药效学等效性。
在本综述中，我们探讨了 IVIg 在治疗各种神经疾病中的疗效。IVIg 的给药仍面临许多挑战。因此，有必要在临床实践中规范 IVIg 的使用。SCIG 给药是治疗慢性炎症性脱髓鞘性多发性神经病和特发性炎性肌病等神经和免疫相关疾病的一种新的可行治疗选择。随着我们对 IVIg 作用机制的理解的提高，潜在的下一代生物制剂可以被开发出来。
